India, April 19 -- Sanofi's (SNY,SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest mRNA vaccine, mNEXSPIKE (mRNA-1283), in the first head-to-head, double-blind, randomized phase 4 study conducted in adults.
The company said the COMPARE study found that Nuvaxovid recipients experienced fewer and less severe systemic side effects such as fatigue, headache, and fever. Severe systemic symptoms that disrupted daily activities occurred in fewer than one in ten Nuvaxovid recipients, compared to one in five among mNEXSPIKE recipients. Severe local reactions at the injection site were also rare with Nuvaxovid, occurring more than 75% less freq...